FierceBiotechOriginal article
{"a":[{"_":"Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability","$":{"href":"/biotech/inhibrxs-profound-dataset-boosts-hopes-accelerated-approval-ox40-agonist","hreflang":"en"}}]}
Phase 2positiveOX40 agonistPositive
AI Analysis
Summary
Inhibrx Biosciences reported positive Phase 2 data for its OX40 agonist in head and neck cancer, demonstrating 9.6 months of progression-free survival. The CEO highlighted the data as evidence of the therapy's durability.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
9.6 months progression-free survival demonstrated
Importance:6/10
Sentiment:
0.70
Phase 2 dataOX40 agonisthead and neck cancerprogression-free survivaldurability
Related Companies
Read the original article
Published by FierceBiotech on September 8, 2026 12:22 AM